Nanometer breviscapine polymer particle preparation and its preparation process
A technology of breviscapine and polymers, applied in the direction of drug combinations, pharmaceutical formulas, medical preparations containing active ingredients, etc., can solve the problems of no product production methods, etc., achieve simple and easy operation, increase curative effect, and prolong cycle time Effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0028] Get breviscapine 5g and polylactic acid 30g, dissolve completely in the mixed solution (2 / 3, v / v) of methanol and acetone of 15ml, then add it dropwise to the aqueous solution of 40ml poloxamer (its mass percentage concentration 3%), stirred at room temperature, completely removed the organic solvent, and then passed through a microporous membrane (0.45 μm) to obtain a scutellarin polymer nanoparticle suspension preparation, the average drug encapsulation efficiency of which was 88%, and the average The particle size is 100-250nm.
[0029] Ethanol and ethyl acetate were used instead of methanol to prepare scutellarin polymer nanoparticle suspension preparations according to the above method, and the average encapsulation rate of the drug was 87-90%, and the average particle size was 100-250nm.
[0030] Take 25, 60, and 100 g of polylactic acid respectively to prepare scutellarin polymer nanoparticle suspension preparation according to the above method. The average encap...
Embodiment 2
[0033] The poloxamer aqueous solution in Example 1 was replaced by the alkyl polyglycoside 0810 aqueous solution with a mass percentage concentration of 0.5%, 2.0%, and 4.0%, respectively, and the scutellarin polymer nanoparticle suspension was prepared according to the method described in Example 1. The preparation has an average drug encapsulation rate of 79-83%, and an average particle diameter of 150-350nm.
Embodiment 3
[0035] Mixtures of various poloxamers and alkyl polyglycosides 0810 were prepared at volume ratios of 1:1, 1:2, 1:3, 1:0.5, 1;0.3. Then take the above-mentioned mixture and add appropriate water respectively to form aqueous solutions with mass percentage concentrations of 0.5%, 2.0%, and 4.0% to replace the poloxamer aqueous solution in Example 1. The scutellarin polymer nanoparticle suspension preparation was prepared according to the method described in Example 1, the average encapsulation rate of the drug was 76-86%, and the average particle size was 100-400nm.
PUM
Property | Measurement | Unit |
---|---|---|
size | aaaaa | aaaaa |
particle size | aaaaa | aaaaa |
particle size | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com